Original Source: 2015 Small-Cap Biotech Watchlist Announced

Release of The Life Sciences Report’s 2015 Small-Cap Biotech Watchlist marks the third year we have brought together a team of analysts at the Biotech Showcase to compile a basket of stocks based on catalyst prospects for the coming year. This year’s experts are some of the leading stock watchers in the space: Mara Goldstein, managing director and senior healthcare analyst at Cantor Fitzgerald; Reni Benjamin, head of equity research and senior healthcare analyst at H.C. Wainwright & Co.; Joe Pantginis.

Matching Channels

Philips Healthcare generated $11.2 billion in sales from its healthcare products in 2010, ranking in the 6th largest medical devices company in the world. With a focus on cardiology and oncology.

Able to take advantage of a 2 European funding stimulus in 2009, the Czech Republic is one of Europes top 5 centers for biotechnology companies. In just over decade, the Czech Republic ha.

India, in the Asian subcontinent is the worlds fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps.

Matching News

By Bret Jensen:As a regular columnist on Real Money Pro, a frequent contributor here on SeekingAlpha and being the editor of the recently launched monthly newsletter Small Cap Gems, I get a lot of que.

Biotech crops have cut pesticide use and increased the net income of small farmers in many countries in Asia, including China -More-

The International Service for the Acquisition of Agri-Biotech Applications (ISAAA) released its report today on the current global plantings of GM Crops.  The report, Global Status of Commercialized.

By Bret Jensen:Over the years, I have learned to watch insider buying within the small cap space to turn up interesting and lucrative new investment ideas. So many times I have seen big moves in these.

That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive.  You may have noticed that more and more seasoned pharma executives are making the move from b.

Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year, according to EP Vantage’s latest report, Pharma & Biotech 2015 Preview. EP Van.